IP Library › Patent Application 18227071
Patent Application
App. No. 18/227,071

PUMP-CONNECTABLE ANALYTE SENSING CANNULA

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
18/227,071
Abstract

Described herein are systems and methods for sensing an analyte concentration and delivering a composition to a subcutaneous space of a subject comprising a sensing cannula, which comprises an electrode for detecting the analyte concentration in the subcutaneous space.

Claims (40)

1 .- 93 . (canceled)

94 . A device for sensing an analyte concentration and delivering a composition into a subcutaneous space, comprising:

a. a sensing cannula comprising an electrode for detecting the analyte concentration in the subcutaneous space, wherein the electrode comprises a redox-catalytic layer;

b. a signal processing module operably coupled to the sensing cannula through a plurality of conductors; and

c. a fluid reservoir configured to deliver the composition through the sensing cannula into the subcutaneous space upon receiving a signal from the signal processing module.

95 . The device of claim 94 , further comprising a housing having a top surface, a base, and one or more vertical walls.

96 . The device of claim 95 , wherein the housing further comprises one or more electrical contacts on the one or more vertical walls.

97 . The device of claim 95 , wherein one or more of the plurality of conductors is contained in the housing.

98 . The device of claim 95 , wherein one or more of the plurality of conductors is disposed on an external surface of the one or more vertical walls of the housing.

99 . The device of claim 94 , wherein the sensing cannula further comprises one or more electrical contacts.

100 . The device of claim 99 , wherein the one or more of the plurality of conductors is in contact with the one or more electrical contacts on the sensing cannula.

101 . The device of claim 99 , wherein one or more of the plurality of conductors is disposed on an exterior surface of the sensing cannula.

102 . The device of claim 94 , wherein one or more of the plurality of conductors is operably coupled to the electrode.

103 . The device of claim 94 , wherein one or more of the plurality of conductors is held in contact with the sensing cannula through a connector.

104 . The device of claim 94 , further comprising a fluid path connecting the fluid reservoir and the sensing cannula.

105 . The device of claim 94 , wherein the redox-catalytic layer comprises a redox mediator and an enzyme.

106 . The device of claim 105 , wherein the redox mediator comprises a metal in a platinum group that is covalently bound to a pyridine-based or imidazole-based ligand.

107 . The device of claim 105 , wherein the enzyme comprises glucose oxidase or glucose dehydrogenase.

108 . The device of claim 105 , wherein the redox mediator and the enzyme allow electron transfer from an analyte in the subcutaneous space to the electrode.

109 . The device of claim 108 , wherein the electron transfer is sufficient to cause a response to an applied bias potential to the electrode of no more than +250 millivolts (mV) relative to a reference electrode.

110 . The device of claim 109 , wherein the response comprises a current.

111 . The device of claim 109 , wherein the applied bias potential to the electrode of no more than +250 mV relative to the reference electrode allows the electrode layer to undergo substantially no electropolymerization of an excipient of the composition during continuous operation of the electrode, thereby maintaining a sensitivity of the electrode to analyte in the presence of the composition.

112 . The device of claim 94 , wherein the electrode comprises an amperometric glucose sensor.

113 . The device of claim 94 , wherein the analyte comprises glucose.

114 . The device of claim 94 , wherein the composition comprises insulin or an insulin analog.

115 . The device of claim 94 , wherein the composition further comprises a pharmaceutical acceptable excipient.

116 . The device of claim 115 , wherein the pharmaceutical acceptable excipient comprises phenol, cresol, a salt, a stabilizing agent, or any combination thereof.

117 . The device of claim 94 , wherein the plurality of conductors comprises a conductive metal or alloy.

118 . The device of claim 94 , wherein the plurality of conductors comprises a compressible conductive rubber.

119 . The device of claim 94 , wherein the plurality of conductors comprises a flexible electronic circuit.

120 . The device of claim 94 , further comprising a spring configured to drive the sensing cannula into the subcutaneous space.

121 . A device for sensing analyte concentration and delivering a composition into a subcutaneous space, the device comprising:

a. a sensing cannula comprising an electrode for detecting an analyte concentration in the subcutaneous space;

b. a signal processing module operably coupled to the sensing cannula through a plurality of conductors; and

c. an electronic pump configured to depress a syringe fluidically connected to a fluid reservoir upon receiving a signal from the signal processing module, wherein depressing the syringe delivers the composition through the sensing cannula into the subcutaneous space.

122 . A method for sensing an analyte concentration and delivering a composition into a subcutaneous space, comprising:

a. providing a sensing cannula, wherein the sensing cannula comprises an electrode for detecting the analyte concentration in the subcutaneous space, wherein the electrode comprises a redox-catalytic layer;

b. inserting the sensing cannula into the subcutaneous space;

c. monitoring, by the sensing cannula, the analyte concentration in the subcutaneous space; and

d. delivering a sufficient amount of the composition through the sensing cannula into the subcutaneous space based at least in part on the monitoring of the analyte concentration.

Assignments (3)
SECURITY INTEREST Recorded Aug 6, 2026
From: PACIFIC DIABETES TECHNOLOGIES, INC.
To: THE DIABETES CARE FOUNDATION
Reel/Frame 075553/0100 →
SECURITY INTEREST Recorded Oct 7, 2025
From: PACIFIC DIABETES TECHNOLOGIES, INC.
To: THE DIABETES CARE FOUNDATION
Reel/Frame 072494/0516 →
SECURITY INTEREST Recorded Jan 18, 2024
From: PACIFIC DIABETES TECHNOLOGIES, INC
To: THE DIABETES CARE FOUNDATION
Reel/Frame 066165/0647 →